BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/5/2022 8:40:56 AM | Browse: 248 | Download: 485
 |
Received |
|
2022-04-13 05:07 |
|
Peer-Review Started |
|
2022-04-13 05:07 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-05-31 07:50 |
|
Revised |
|
2022-06-14 05:50 |
|
Second Decision |
|
2022-06-27 03:08 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2022-06-27 19:04 |
|
Articles in Press |
|
2022-06-27 19:04 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-06-28 07:24 |
|
Publish the Manuscript Online |
|
2022-07-05 08:40 |
| ISSN |
2308-3840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Difference in incidence of developing hepatocellular carcinoma between hepatitis B virus-and hepatitis C virus-infected patients
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Kazuo Tarao, Akito Nozaki, Hirokazu Komatsu, Naomi Ideno, Tatsuji Komatsu, Takaaki Ikeda, Masataka Taguri and Shin Maeda |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Kazuo Tarao, MD, PhD, Director, Deparment of Gastroenterology, Tarao's Gastroenterological Clinic, 3rd Floor, Taiyo-Building,
2-58-6, Futamatagawa,
Asahi-ku, , Yokohama city 241-0821, Japan. duoluoweih7@gmail.com |
| Key Words |
Hazard ratio of alanine aminotransferase; Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma; Elevated alanine aminotransferase |
| Core Tip |
It is generally accepted that the incidence of hepatocellular carcinoma (HCC) in hepatitis C virus (HCV)-associated of patients is higher than that in hepatitis B virus (HBV)-associated patients. We demonstrated that the incidence of HCC in HCV-associated cirrhotic patients was 4.81%/year as compared with 3.23% in HBV-associated patients based on analytic assessment of already published papers. In HBV infection, alanine aminotransferase (ALT) is the second highest risk factor, and in HCV infection, ALT is the highest risk factor, for HCC development. The hazard ratio (HR) for developing HCC in the inflammatory state (serum ALT levels exceeded the normal range) was compared between HBV and HCV patients. In the 14 studies of HBV patients, the average HR was 2.74 as compared with 5.51 in the 8 studies of HCV patients (P = 0.0391). The difference in the incidence of HCC development between HBV and HCV patients may depend on the difference in the hazard risk of ALT for HCC development between HBV and HCV infections. |
| Publish Date |
2022-07-05 08:40 |
| Citation |
Tarao K, Nozaki A, Komatsu H, Ideno N, Komatsu T, Ikeda T, Taguri M, Maeda S. Difference in incidence of developing hepatocellular carcinoma between hepatitis B virus-and hepatitis C virus-infected patients. World J Meta-Anal 2022; 10(3):186-194 |
| URL |
https://www.wjgnet.com/2308-3840/full/v10/i3/186.htm |
| DOI |
https://dx.doi.org/10.13105/wjma.v10.i3.186 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
